Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 4(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02557269Phase 4Unknown

4"S" - Seasonal Symptoms Suppression Study

Role: lead

NCT01986582Phase 2Completed

NoAL (HPMC) in Combination With Oxymetazoline in Patients With Allergic Rhinitis

Role: lead

NCT01250652Phase 4Completed

Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses

Role: lead

NCT01754220Phase 4Completed

Open-label Study of the Effects of Montelukast in Patients With Chronic Cough

Role: lead

All 4 trials loaded